iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

iNtRON Biotechnology has announced that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.

Scroll to Top